<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">rsp</journal-id><journal-title-group><journal-title xml:lang="ru">Научно-практическая ревматология</journal-title><trans-title-group xml:lang="en"><trans-title>Rheumatology Science and Practice</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1995-4484</issn><issn pub-type="epub">1995-4492</issn><publisher><publisher-name>IMA-PRESS, LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.14412/1995-4484-2007-31-34</article-id><article-id custom-type="elpub" pub-id-type="custom">rsp-2184</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL RESEARCH</subject></subj-group></article-categories><title-group><article-title>АНТИТЕЛА К АННЕКСИНУ-5 У БЕРЕМЕННЫХ С СИСТЕМНОЙ КРАСНОЙ ВОЛЧАНКОЙ</article-title><trans-title-group xml:lang="en"><trans-title>Antibodies to annexin-5 in pregnant women with systemic lupus erythematosus</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Алекберова</surname><given-names>З. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Alekberova</surname><given-names>Z. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Адрес: 115522 Москва, Каширское шоссе, 34а, Тел/факс: 8-499-614-44-52</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кошелева</surname><given-names>Н. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Kosheleva</surname><given-names>N. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Адрес: 115522 Москва, Каширское шоссе, 34а, Тел/факс: 8-499-614-44-52</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Александрова</surname><given-names>Е. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Alexandrova</surname><given-names>E. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Адрес: 115522 Москва, Каширское шоссе, 34а, Тел/факс: 8-499-614-44-52</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Хузмиева</surname><given-names>С. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Husmieva</surname><given-names>S. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Адрес: 115522 Москва, Каширское шоссе, 34а, Тел/факс: 8-499-614-44-52</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Новиков</surname><given-names>А. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Novikov</surname><given-names>A. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Адрес: 115522 Москва, Каширское шоссе, 34а, Тел/факс: 8-499-614-44-52</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Насонов</surname><given-names>Е. Л.</given-names></name><name name-style="western" xml:lang="en"><surname>Nasonov</surname><given-names>E. L.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Адрес: 115522 Москва, Каширское шоссе, 34а, Тел/факс: 8-499-614-44-52</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru">ГУ Институт ревматологии РАМН, Москва<country>Россия</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2007</year></pub-date><pub-date pub-type="epub"><day>12</day><month>05</month><year>2016</year></pub-date><volume>45</volume><issue>4</issue><fpage>31</fpage><lpage>34</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Алекберова З.С., Кошелева Н.М., Александрова Е.Н., Хузмиева С.И., Новиков А.А., Насонов Е.Л., 2016</copyright-statement><copyright-year>2016</copyright-year><copyright-holder xml:lang="ru">Алекберова З.С., Кошелева Н.М., Александрова Е.Н., Хузмиева С.И., Новиков А.А., Насонов Е.Л.</copyright-holder><copyright-holder xml:lang="en">Alekberova Z.S., Kosheleva N.M., Alexandrova E.N., Husmieva S.I., Novikov A.A., Nasonov E.L.</copyright-holder><license license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://rsp.mediar-press.net/rsp/article/view/2184">https://rsp.mediar-press.net/rsp/article/view/2184</self-uri><abstract><sec><title>Цель</title><p>Цель. Определить динамику антител к аннексину-5 (аАnx5) у беременных с системной красной волчанкой (СКВ) и их влияние на исход гестации.</p></sec><sec><title>Материал и методы</title><p>Материал и методы. Обследовано 15 беременных с достоверной СКВ (критерии ACR, 1997), из них 4 – с сопутствующим антифосфолипидным синдромом (АФС). Медиана возраста пациенток – 28,0 (23-33) лет, длительность СКВ – 4,0 (3-9) года, активность по SLEPDAI к началу беременности 2 (2-11) балла. Все, кроме одной больной, принимали метипред от 2 до 20 мг/сут. Обследование беременных осуществлялось в каждом триместре гестации. Определение аАnx5 и антикардиолипиновых антител (аКЛ) в сыворотках крови проводилось иммуноферментным методом.</p></sec><sec><title>Результаты</title><p>Результаты. Повышение аАnx5 было выявлено у 7 беременных (1-ая группа): 6 – позитивны только по IgG-аАnx5, одна – как по IgG-, так и IgM-аАnx5; изолированного повышения IgM-аАnx5 не отмечалось. У 4-х пациенток показатели IgG-аАnx5 были пограничными (от 5,3 до 7,4 Ед/мл), у 3-х они составили соответственно 9,6; 12,1 и 168,5 Ед/мл. Последняя больная была также позитивна по IgM-аАnx5 (до 14,4 Ед/мл). Повышение аАnx5 наблюдалось чаще и достигало наибольших величин во II-ом триместре беременности. У 8 беременных с СКВ (2-ая группа) повышения IgG- и IgM-аАnx5 не выявлялось. 11 из 15 беременностей завершились родами жизнеспособным младенцем, остальные 4 имели неблагоприятный исход гестации. Средние сроки родоразрешения в сравниваемых группах больных не отличались, их медиана составила 36 нед. Потери беременности имели место у 3-х пациенток с нормальными показателями аАnx5 и одной – позитивной по aAnx5. Трое из этих 4 больных были позитивными и по аКЛ, у 2-х из них ранее диагностирован АФС.</p></sec><sec><title>Заключение</title><p>Заключение. Повышение IgG-аАnx5 встречалось почти у половины беременных пациенток с СКВ (у 7 из 15), преимущественно во II-ом триместре гестации. Неблагоприятные исходы беременности не ассоциировались с повышением аАnx5. Возможно, низкие уровни позитивности аАnx5 и малочисленность обследованных могли повлиять на полученные результаты.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Objective</title><p>Objective. To assess change of annexin-5 antibodies (AA5) level and AA5 influence on gestation outcome in pregnant women with systemic lupus erythematosus (SLE).</p></sec><sec><title>Material and methods</title><p>Material and methods. 15 pregnant women with SLE who fulfilled 1997 ACR criteria (4 of them with concomitant antiphospholipid syndrome – APS) were included. Median age of pts was 28,0 (23- 33) years, median SLE duration – 4,0 (3-9) years. SLEDAI activity score at the beginning of gestation was 2 (2-11). All but one pts received metypred from 2 to 20 mg/day. The women were examined in every trimester of gestation. AA5 and anticardiolipine antibodies (ACLA) were evaluated with immunoenzyme assay.</p></sec><sec><title>Results</title><p>Results. AA5 elevation was revealed in 7 women (group 1): 6 of them were only IgG AA5 positive, 1 had both IgG and IgM AA5. Isolated IgM AA5 elevation was absent. 4 pts had borderline IgG AA5 values (from 5,3 to 7,4 U/ml). 3 pts had respectively 9,6, 12,1 and 168,5 U/ml. The last pt was also positive for IgM AA5 (till 14,4 U/ml). AA5 elevation was more frequent and more prominent during the II trimester of gestation. 8 pts with SLE (group 2) did not have AA5 elevation. 11 from 15 gestations ended with birth of viable baby, the rest 4 had unfavorable outcome. Median terms of delivery did not differ in both groups and came to 36 weeks. 3 pts with normal AA5 and 1 pt with elevated AA5 had gestation lost. 3 from these 4 pts were ACLA positive and APS was earlier diagnosed in 2 from them.</p></sec><sec><title>Conclusion</title><p>Conclusion. Almost half of pregnant women with SLE (7 from 15) had AA5 elevation mainly during the II trimester of gestation. Unfavorable gestation outcomes were not associated with AA5 elevation. Possibly low levels of AA5 positivity and small sample size could influence the results.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>системная красная волчанка</kwd><kwd>беременность</kwd><kwd>антитела к аннексину-5</kwd></kwd-group><kwd-group xml:lang="en"><kwd>systemic lupus erythematosus</kwd><kwd>gestation</kwd><kwd>annexin-5 antibodies</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Volker G., Moss S.E. Annexin: from structure to functions. Physiol.Rev., 2002, 82, 331-371</mixed-citation><mixed-citation xml:lang="en">Volker G., Moss S.E. Annexin: from structure to functions. Physiol.Rev., 2002, 82, 331-371</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Masuda J., Takayama E., Satoh A. et al. Levels of annexin IV and V in the plasma of pregnant and pastpartum women. Throm.Haemost., 2004, 91, 1129-1136</mixed-citation><mixed-citation xml:lang="en">Masuda J., Takayama E., Satoh A. et al. Levels of annexin IV and V in the plasma of pregnant and pastpartum women. Throm.Haemost., 2004, 91, 1129-1136</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Gonzalez-Conejero R., Corral J., Roldon V. et al. A common polymorphism in the annexin V Kozak sequence (-1C&gt;T) increases translation efficiency and plasma levels of annexin V, and decreases the risk of myocardial infarction in young patients. Blood, 2002, 15, 2081-2086</mixed-citation><mixed-citation xml:lang="en">Gonzalez-Conejero R., Corral J., Roldon V. et al. A common polymorphism in the annexin V Kozak sequence (-1C&gt;T) increases translation efficiency and plasma levels of annexin V, and decreases the risk of myocardial infarction in young patients. Blood, 2002, 15, 2081-2086</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Buyon J.P., Kalunian K.C., Ramsey-Goldman R. et al. Assessing disease activity in SLE patients during pregnancy. Lupus, 1999, 8, 677-684</mixed-citation><mixed-citation xml:lang="en">Buyon J.P., Kalunian K.C., Ramsey-Goldman R. et al. Assessing disease activity in SLE patients during pregnancy. Lupus, 1999, 8, 677-684</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Bizzaro N., Tonutti E., Villata D. et al. Prevalence and clinical correlation of anti-phospholipid-binding protein antibodies in anticardiolipin-negative patients with systemic lupus erythematosus and women with unexplained recurrent miscarriages. Arch.Pathol.Lab.Med., 2005, 129, 61-68</mixed-citation><mixed-citation xml:lang="en">Bizzaro N., Tonutti E., Villata D. et al. Prevalence and clinical correlation of anti-phospholipid-binding protein antibodies in anticardiolipin-negative patients with systemic lupus erythematosus and women with unexplained recurrent miscarriages. Arch.Pathol.Lab.Med., 2005, 129, 61-68</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Bizzaro N., Antico A., Mussso M et al. A prospective study of 1038 pregnancies on the predictive value of antiannexin V antibodies for fetal loss. Ann. N.Y.Acad.Sci, 2005, 1050, 348-356</mixed-citation><mixed-citation xml:lang="en">Bizzaro N., Antico A., Mussso M et al. A prospective study of 1038 pregnancies on the predictive value of antiannexin V antibodies for fetal loss. Ann. N.Y.Acad.Sci, 2005, 1050, 348-356</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">de Laat B., Derksen R.H.W.M., Mackie I.J. et al. Annexin A5 polymorphism (-1C→T) and the presence of anti-annexin A5 antibodies in antiphospholipid syndrome. Ann.Rheum.Dis., 2006, 65, 1468-1472</mixed-citation><mixed-citation xml:lang="en">de Laat B., Derksen R.H.W.M., Mackie I.J. et al. Annexin A5 polymorphism (-1C→T) and the presence of anti-annexin A5 antibodies in antiphospholipid syndrome. Ann.Rheum.Dis., 2006, 65, 1468-1472</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Van Eerden P., Wu X.X., Chazotte C. et al. Annexin A5 levels in midtrimester amniotic fluid: association with intrauterine growth restriction. Am.J.Obstet. Gynecol., 2006, 194, 1371-1376</mixed-citation><mixed-citation xml:lang="en">Van Eerden P., Wu X.X., Chazotte C. et al. Annexin A5 levels in midtrimester amniotic fluid: association with intrauterine growth restriction. Am.J.Obstet. Gynecol., 2006, 194, 1371-1376</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
